News

Pulmonx’s  Zephyr Endobronchial Valve significantly reduces breathlessness and improves physical activity and quality of life in people with severe emphysema, a post-hoc analysis of clinical trial data shows. The study, “Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels and Quality of Life at One…

People with chronic obstructive pulmonary disease (COPD) have three unusual stem cell subsets in their lungs that, together, seem to contribute to the inflammation, tissue scarring, and excessive mucus secretion that characterizes the condition, a recent study has found. The research suggests that changes in lung stem cells,…

Triple therapy with fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) can reduce mortality rates among people with chronic obstructive pulmonary disease (COPD) more than VI treatment with either FF or UMEC, a new analysis of trial data suggests. The findings were published in the American…

New official guidelines have been published by the American Thoracic Society (ATS) for the treatment of chronic obstructive pulmonary disease (COPD). Among the new recommendations, the combination of long-acting beta two agonists (LABA) and long-acting muscarinic antagonists (LAMA) is recommended over either therapy alone to treat people with COPD…

MP1032, an anti-inflammatory molecule developed by MetrioPharm, inhibits the formation of 3-nitrotyrosine — a biomarker of nitrogen reactive species — induced by cigarette smoke in the air sacs of a lung model of chronic obstructive pulmonary disease (COPD), a study has found. The research suggests that MP1032…

People with chronic obstructive pulmonary disease (COPD) need to continue to use maintenance medications as prescribed throughout the COVID-19 pandemic, and do all they can to avoid infection, the American Lung Association said in an update. This virus poses a considerably greater risk of serious complications to these patients and…

A single dose of a pressurized metered-dose inhaler formulation of ensifentrine (RPL544) significantly improved lung function, compared to a placebo, in people with moderate-to-severe chronic obstructive pulmonary disease (COPD), Verona Pharma announced. These results are from part A, the single-dose part, of a Phase 2 trial (NCT04091360) underway in two…